

# SCIENTIFIC PROGRAMME – TUESDAY 25<sup>th</sup> OCTOBER 2005

08.30-10.30	REGISTRATION AND COFFEE
-------------	-------------------------

PARALLEL SESSIONS			
10.30-12.30	<b>SESSION 1</b> Joint Symposium with the British Hypertension Society <i>Argyll 1</i>	<b>SESSION 2</b> Joint Symposium with the European Society of Vascular Surgery Keynote Lecture	<b>SESSION 3</b> Angiogenesis (Sponsored by Genzyme) <i>Castle 1 &amp; 2</i>
12.30-13.00	<b>SESSION 4</b> Keynote Lecture <i>Argyll 1</i>	Debate <i>Argyll 2</i>	<b>SESSION 5</b> Keynote Lecture <i>Castle 1 &amp; 2</i>

**10.30-12.30**      **SESSION 1**  
**Joint Symposium with the British Hypertension Society**  
**Treatment of Hypertension**  
 Chairmen:      D Clement (Belgium)  
                     T MacDonald (UK)

10.30-10.55      1.1      The role of aldosterone in cardiovascular disorders  
 J Connell (UK)

10.55-11.00      Discussion

11.00-11.25      1.2      Treatment of hypertension in stroke  
 P Bath (UK)

11.25-11.30      Discussion

11.30-11.55      1.3      Relationship between hypertension and PAD  
 R Donnelly (UK)

11.55-12.00      Discussion

12.00-12.25      1.4      The ASCOT study and hypertension guidelines  
 G Bevers (UK)

12.25-12.30      Discussion

**10.30-13.00**      **SESSION 2**  
**Joint Symposium with the European Society of Vascular Surgery**  
**KEYNOTE LECTURE**  
 Chairman:      H Sillesen (Denmark)

10.30-10.55      2.1      Treatment options for carotid artery disease  
*Speaker to be confirmed*

10.55-11.00      Discussion

11.00-12.30      2.2      DEBATE - 'to EVAR or not to EVAR?'  
 Chairmen:      C Liapis (Greece)  
                     R Vohra (UK)

Small aneurisms should be treated endovascularily  
*Speaker to be confirmed*

Small aneurisms should not be treated  
 M Horrocks (UK)

## TUESDAY 25<sup>th</sup> OCTOBER 2005 CONTINUED

Only aneurisms with the appropriate anatomy should be treated  
J Fernandes e Fernandes (Portugal)

Almost all aneurisms can and should be treated endovascularily  
*Speaker to be confirmed*

**10.30-12.30**

### SESSION 3

#### Angiogenesis – Sponsored by Genzyme

Chairmen: D Bates (UK)  
S Nikol (Germany)

10.30-11.05 3.1 Endogenous inhibitory splice variants of VEGF  
D Bates (UK)

11.05-11.10 Discussion

11.10-11.45 3.2 Control of angiogenesis by MSF and the extracellular matrix  
A Schor (UK)

11.45-11.50 Discussion

11.50-12.25 3.3 Harnessing the tissue response to hypoxia: clinical experience with a constitutively active HIF -  
1 $\alpha$  transgene for therapeutic angiogenesis  
R Kelly (USA)

12.25-12.30 Discussion

**12.30-13.00**

### SESSION 4

#### KEYNOTE LECTURE

Chairman: D Patterson (UK)

12.30-12.55 4.1 Putting trials into practice: the importance of achieving blood pressure targets  
T Macdonald (UK)

12.55-13.00 Discussion

**12.30-13.00**

### SESSION 5

#### KEYNOTE LECTURE

Chairman: S Schor (UK)

12.30-12.55 5.1 Regulatory aspects of cell and gene therapy products  
K Cichutik (Germany)

12.55-13.00 Discussion

**13.00-14.30**

**LUNCH, IUA GENERAL ASSEMBLY, POSTER VIEWING and EXHIBITION**

### PARALLEL SESSIONS

PARALLEL SESSIONS			
<b>14.30-16.00</b>	<b>SESSION 6</b> Research Papers Hypertension and Risk <i>Argyll 1</i>	<b>SESSION 7</b> Joint Symposium between North American and European Chapters of IUA <i>Argyll 2</i>	<b>SESSION 8</b> TASC <i>Castle 1 &amp; 2</i>
	<b>SESSION 9</b> IUA Prize Research Papers <i>Ayyll 1</i>		<b>SESSION 10</b> Keynote Lecture <i>Castle 1 &amp; 2</i>

## TUESDAY 25<sup>th</sup> OCTOBER 2005 CONTINUED

14.30-15.10

### SESSION 6

#### RESEARCH PAPERS - Hypertension and Risk

Chairmen: G Agnelli (Italy)  
A Gottsäter (Sweden)

- 14.30-14.40 6.1 Insulin resistance and blood pressure circadian variation in an obese hypertensive population  
EJ Diamantopoulos, E Andreadis, G Tsourous, P Katsanou, D Georgiopoulos, M Kakou, M Fotia, A Antoniou, SA Raptis (Greece)
- 14.40-14.50 6.2 Cardiovascular effects of Berberis vulgaris (B.V.) aqueous extract on hypertensive rats and its probable mechanisms  
A Ghorbani, Z Fatehi Hasanabad, M Fatehi, K Farokhfal (Iran)
- 14.50-15.00 6.3 Sildenafil monotherapy is a durable chronic therapy for pulmonary hypertension  
M Pritzker, R Groebner, B Filice (USA)
- 15.00-15.10 6.4 Effects of the antiphospholipid antibodies on the endothelial vascular reactivity  
C Belizna, V Richard, A Lartigue, D Gilbert, F Tron, H Levesque, C Thuillez (France)

14.30-16.00

### SESSION 7

#### Joint Symposium between North American and European Chapters of IUA Clinical Validation of the Relative Safety and Efficacy of Newer Anticoagulants and Related Drugs: Guidelines, Consensus Reports and Recommendations

Chairmen: G Lowe (UK)  
J Fletcher (Australia)

- 14.30-14.45 7.1 New anticoagulant drugs in the management of vascular disorders  
O Iqbal (USA)
- 14.45-15.00 7.2 Validation of clinical trials, registry, quality assurance and regulatory requirements  
G Lowe (UK)
- 15.00-15.15 7.3 Clinical validation and comparative studies: a consensus on consensus  
O Dahl (USA)
- 15.15-15.30 7.4 International consensus statement on the management of VTE  
A Nicolaides (UK) and E Kalodiki
- 15.30-15.45 7.5 Guideline implementation and dissemination: the Australia / New Zealand chapter initiative  
J Fletcher (Australia)
- 15.45-16.00 Open forum  
All speakers

14.30-15.15

### SESSION 8

#### TASC

Chairmen: L Norgren (Sweden)  
W Hiatt (USA)

- 14.30-14.40 8.1 TASC II - Why, how and when?  
L Norgren (Sweden)
- 14.40-14.45 Discussion
- 14.45-14.55 8.2 What is new in epidemiology of PAD  
G Fowkes (UK)
- 14.55-15.00 Discussion

## TUESDAY 25<sup>th</sup> OCTOBER 2005 CONTINUED

- 15.00-15.10 8.3 What is new in intermittent claudication?  
W Hiatt (USA)
- 15.10-15.15 Discussion
- 15.10-16.00** **SESSION 9**  
**IUA PRIZE RESEARCH PAPERS**  
Chairmen: G Agnelli (Italy) Adjudicators: A Nicolaidis (UK)  
A Gottsater (Sweden) S Novo (Italy)
- 15.10-15.20 9.1 Intensive insulin therapy improves endothelial function and  
microvascular reactivity in young people with type 1 diabetes  
VL Franklin, M McLaren, F Khan, G Kennedy, SA Greene, J Belch (UK)
- 15.20-15.30 9.2 Predictive value of ankle/brachial index relative to dobutamine  
stress echocardiography for cardiovascular morbidity and mortality  
in patients with peripheral arterial disease  
MR Thatipelli, PA Pellikka, TW Rooke, RD McBane, WE Wysokinski (USA)
- 15.30-15.40 9.3 Self-reported peripheral arterial disease and vascular events in  
the Northern Manhattan Study  
M Salameh, T Rundek, Z Jin, E Ratchford, B Boden-Albala, R Stahl,  
D Jacoby, S Homma, RL Sacco (USA)
- 15.40-15.50 9.4 Increased angiogenesis and vascular endothelial subtypes  
characterisation in human critical limb ischaemia  
TK Ho, V Rajkumar, K Khan, C Hart, C DiSalvo, RK Walesby, DJ Abraham,  
CM Black, DM Baker (UK)
- 15.50-16.00 9.5 Arterial wall thickness and rigidity in antiphospholipid syndrome  
patients  
C Belizna, E Primard, JM Kerleau, N Cailleux, JP Louvel, H Levesque (France)
- 15.15-16.00** **SESSION 10**  
**KEYNOTE LECTURE**  
Chairman: J Regensteiner (USA)
- 15.15-15.55 10.1 Quality of life: fishing in muddy waters  
S Hunt (UK)
- 15.55-16.00 Discussion
- 16.00-16.30** **TEA, EXHIBITION and POSTER VIEWING**

### PARALLEL SESSIONS

PARALLEL SESSIONS			
<b>16.30-17.30</b>	<b>SESSION 11</b> <b>IUA Prize Research Papers</b> <i>Argyll 1</i>	<b>SESSION 12</b> <b>Research Papers</b> <b>General Vascular</b> <i>Argyll 2</i>	<b>SESSION 13</b> <b>Keynote Lecture</b> <i>Castle 1 &amp; 2</i>

- 16.30-17.20** **SESSION 11**  
**IUA PRIZE RESEARCH PAPERS**  
Chairmen: G Agnelli (Italy) Adjudicators: A Nicolaidis (UK)  
A Gottsäter (Sweden) S Novo (Italy)
- 16.30-16.40 11.1 Improvement of vascular depression after carotid artery stenting  
WM Mlekusch, IM Mlekusch, EM Minar, JL Lehrner, MH Haumer,  
MS Schillinger  
(Austria)

## TUESDAY 25<sup>th</sup> OCTOBER 2005 CONTINUED

- 16.40-16.50 11.2 Clinical characteristics of patients with premature lower extremity atherosclerosis associated with familial early cardiovascular disease and/or cancer  
PJ Levy, SA Jackson, T McCoy, CM Ferrario (USA)
- 16.50-17.00 11.3 A modified calculation of ankle brachial pressure index is far more sensitive in the detection of peripheral arterial disease  
F Schröder, S Kareem, U Zwedler, H Lawall, C Diehm (Germany)
- 17.00-17.10 11.4 A randomised trial of intravenous iloprost (a stable prostocyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease  
AK Bozkurt, C Koksak, MY Demirbas, A Erdogan, A Rahman, U Demirkiliç, H Ustunsoy, G Onem, L Yillik, H Onol, B Cinar, M Karacelik, I Erdinc, C Bolcal, AG Sayin (Turkey)
- 17.10-17.20 11.5 High resolution MRA digital arteriograms  
M Pritzker (USA)
- 16.30-17.20** **SESSION 12**  
**RESEARCH PAPERS – General Vascular**  
Chairmen: A Drooz (Austria)  
J Froechlich (USA)
- 12.1 This oral presentation has been withdrawn by the author
- 16.30-16.40 12.2 Gender differences in outcome of conservatively treated patients with asymptomatic high grade carotid stenosis  
PD Dick, CS Sherif, SS Sabeti, JA Amighi, EM Minar, MS Schillinger (Austria)
- 16.40-16.50 12.3 N-acetylcysteine (NAC) in preventing contrast-related nephropathy - a meta-analysis  
M Gawenda, A Möller, G Wassmer, J Brunkwall (Germany)
- 16.50-17.00 12.4 Preventing a secondary cardiovascular event by a minimal smoking cessation program in an outpatient clinic: Is it worth the effort?  
MN Storm-Versloot, H Vermeulen, LCW Wiggers, EMA Smets, JCJ de Haes, LB van Loenen, RJG Peters, DA Legemate, R de Vos (The Netherlands)
- 17.00-17.10 12.5 Common to internal carotid artery bypass grafting with PTFE graft as an alternative technique to standard endarterectomy  
SA Makris, N Bessias, J Boudouris, D Maras, P Pavlidis, T Kotsis, S Georgopoulos, E Bastounis (Greece)
- 17.10-17.20 12.6 The success of routine MRSA screening in vascular surgery: a nine year review  
DJ Malde, A Abidia, A Nasim, CN McCollum, M Welch (UK)
- 16.30-17.30** **SESSION 13**  
**KEYNOTE LECTURE**  
Chairman: L Norgren (Sweden)
- 16.30-17.20 13.1 Pathophysiology of claudication: interplay between haemodynamic and metabolic limitations  
W Hiatt (USA)
- 17.20-17.30 Discussion
- 18.30-20.00 **WELCOME RECEPTION**  
Glasgow Science Centre

# SCIENTIFIC PROGRAMME – WEDNESDAY 26<sup>th</sup> OCTOBER 2005

## PARALLEL SESSIONS

08.00-10.30	<b>SESSION 1</b> 4 <sup>th</sup> TransAtlantic Vascular Meeting (TAVM) <i>Argyll 1</i>	<b>SESSION 14</b> Prevention and Treatment of Venous Thromboembolism Sponsored by GlaxoSmithKline <i>Argyll 2</i>	<b>SESSION 15</b> Joint Symposium with the Working Group on Peripheral Circulation of the European Society of Cardiology <i>Castle 1 &amp; 2</i>
10.00-10.30		<b>SESSION 16</b> Research Papers <i>Argyll 2</i>	

### 4<sup>th</sup> TransAtlantic Vascular Meeting (TAVM)

Sponsored by Cordis Endovascular USA, Abbott, Genzyme, Sigma Tau, Wyeth, Mitsubishi, Gore, CV Therapeutics

### Novel Insights: from Basic Science to Clinical Investigation: The State of the Art in 2005

08.00-09.15

#### SESSION 1 - TAVM

#### A: Insights from Epidemiological Studies of Vascular Disease

Chairmen: J Belch (UK)  
J Regensteiner (USA)

- |              |     |  |
|--------------|-----|--|
| 08.00-08.15  | A.1 | Introduction<br>J Regensteiner (USA)   |
| 08.15-08.30  | A.2 | New epidemiologic insights into PAD: the Edinburgh artery study<br>G Fowkes (UK)               |
| 08.30-08.45  | A.3 | New epidemiologic insights into PAD: the US perspective<br>A Hirsch (USA)                      |
| 08.45-09.00  | A.4 | Epidemiologic insights on PAD: the power of the ankle-brachial index<br>M Criqui (USA)         |
| 09.00-09.15  |     | Discussion   |
| 09.15-10.45  |     | <b>SESSION 1 - TAVM</b><br><b>B: Translational Vascular Medicine / Biology</b>                 |
| 09.15-09.30  | B.1 | Role of endothelial dysfunction in atherosclerosis<br>J Cooke (USA)                            |
| 09.30-09.45  | B.2 | Inflammation and coagulation in aortic aneurismal disease<br>A Gottsäter (Sweden)              |
| 09.45-10.00  | B.3 | The role of diabetes in the pathogenesis and manifestations of PAD<br>M Creager (USA)          |
| 10.00-10.15  | B.4 | Screening for atherosclerotic disease<br>A Nicolaides (UK)                                     |
| 10.15.-10.30 | B.5 | Effects of a thiazolidinedione on exercise capacity in Type 2 diabetes<br>J Regensteiner (USA) |
| 10.30-10.45  |     | Discussion   |

## WEDNESDAY 26<sup>th</sup> OCTOBER 2005 CONTINUED

08.00-10.00

### SESSION 14

#### Prevention and Treatment of Venous Thromboembolism Sponsored by GlaxoSmithKline

Chairmen: G Lowe (UK)  
A Cohen (UK)

- 08.00-08.30 14.1 Surgical thromboprophylaxis  
J Skinner (UK)
- 08.30-08.40 Discussion
- 08.40-09.10 14.2 Medical thromboprophylaxis  
A Cohen (UK)
- 09.10-09.20 Discussion
- 09.20-09.50 14.3 Treatment of VTE including DVT and PTE  
G Agnelli (Italy)

09.50-10.00

Discussion

08.00-10.30

### SESSION 15

#### Joint Symposium with the Working Group on Peripheral Circulation of the European Society of Cardiology Supported by the European Society of Cardiology

#### Atherosclerosis-systemic disease-systemic approach

Chairmen: L Norgren (Sweden)  
M Ciccone (Italy)

- 08.00-08.25 15.1 Atherogenetic mechanisms and morphologic characteristics of atherosclerotic lesions in different locations – are they identical?  
S Novo (Italy)
- 08.25-08.30 Discussion
- 08.30-08.55 15.2 Diagnostic approach to the patient with suspicion of multifocal disease  
A Nicolaides (UK)
- 08.55-09.00 Discussion
- 09.00-09.25 15.3 Do preventative measures depend on location of atherosclerotic process?  
P Poredos (Slovenia)
- 09.25-09.30 Discussion
- 09.30-09.55 15.4 Multifocal atherosclerotic disease and the risk for cardiovascular events  
D Clement (Belgium)
- 09.55-10.00 Discussion
- 10.00-10.25 15.5 Invasive access to the patient with multifocal atherosclerosis  
J Fernandes e Fernandes (Portugal)
- 10.25-10.30 Discussion

## WEDNESDAY 26<sup>th</sup> OCTOBER 2005 CONTINUED

**10.00-10.40**                    **SESSION 16**  
**RESEARCH PAPERS - Venous Disease**  
**Sponsored by GlaxoSmithKline**  
 Chairmen:        D Bergqvist (Sweden)  
                       M Cairols (Spain)

- 10.00-10.10    16.1    The role of the axillo-iliac segment in renal dialysis  
M Hamish, J Shalhoub, CD Rodd, AH Davies (UK)
- 10.10-10.20    16.2    An "all-comers" duplex scanning policy in patients with varicose  
 veins: is it justified?  
SA Makris, CD Karkos, S Awad, NJM London (UK)
- 10.20-10.30    16.3    An elevated level of serum cytokines (VEGF, TNF-alpha) in patients  
 with venous insufficiency  
WD Drozd, KSZ Sztefko, MD Dolecki, JK Kulawik (Poland)
- 10.30-10.40    16.4    Mesenteric vein thrombosis: a heterogeneous clinical entity  
MR Thatipelli, RD McBane, TW Rooke, WE Wysokinski (USA)

**10.30-11.00**                    **COFFEE, EXHIBITION and POSTER VIEWING**

### PARALLEL SESSIONS

<b>11.00-12.30</b>	<b>SESSION 1 CONTINUED</b> <b>4<sup>th</sup> TransAtlantic Vascular Meeting (TAVM)</b> <i>Argyll 1</i>	<b>SESSION 17</b> <b>Vascular Disease and Rheumatoid Arthritis</b> <i>Argyll 2</i>	<b>SESSION 18</b> <b>Joint Symposium with the British Society of Interventional Radiology and The British Society of Cardiovascular Magnetic Resonance</b> <i>Castle 1 &amp; 2</i>
<b>12.30-13.00</b>		<b>SESSION 19</b> <b>Keynote Lecture</b> <i>Argyll 2</i>	<b>SESSION 20</b> <b>Keynote Lecture</b> <i>Castle 1 &amp; 2</i>

### 4<sup>th</sup> TransAtlantic Vascular Meeting (TAVM)

- 11.00-13.00**                    **SESSION 1 CONTINUED**  
**C: Insights from Clinical Trials**  
 Chairmen:        M Jaff (USA)  
                       J Olin (USA)
- 11.00-11.15    C.1    Update on angiogenesis and critical limb ischemia  
 S Rajagopalan (USA)
- 11.15-11.30    C.2    Sarpogrelate in intermittent claudication  
 L Norgren (Sweden)
- 11.30-11.45    C.3    CHARISMA trial  
*Speaker to be confirmed*
- 11.45-12.00    C.4    REACH registry  
 A Hirsch (USA)
- 12.00-12.15    C.5    AGATHA study update  
 G Agnelli (Italy)
- 12.15-12.30    C.6    Lipid trials for claudication  
 E Mohler (USA)

## WEDNESDAY 26<sup>th</sup> OCTOBER 2005 CONTINUED

12.30-12.55 A TAVM Keynote Lecture  
Why is the SFA different? The challenge of the SFA for the intervention  
M Jaff (USA)

12.55-13.00 Discussion

**11.00-12.30** **SESSION 17**  
**Vascular Disease and Rheumatoid Arthritis**  
Chairmen: A Herrick (UK)  
D Symmons (UK)

11.00-11.17 17.1 Epidemiology of cardiovascular disease in rheumatoid arthritis  
D Symmons (UK)

11.17-11.22 Discussion

11.22-11.39 17.2 Large vessel disease in rheumatoid arthritis  
J Belch (UK)

11.39-11.44 Discussion

11.44-12.01 17.3 Systemic rheumatoid disease  
R Luqmani (UK)

12.01-12.06 Discussion

12.06-12.23 17.4 Raynaud's phenomenon in rheumatoid arthritis  
A Herrick (UK)

12.23-12.28 Discussion

**11.00-12.30** **SESSION 18**  
**Joint Symposium with the British Society of Interventional Radiologists and the British Society of Cardiovascular Magnetic Resonance**  
**Renovascular Disease**

Chairmen: G Houston (UK)  
H Dargie (UK)  
I Baumgartner (Switzerland)

11.00-11.25 18.1 Renovascular disease: the nephrologists view  
P Kalra (UK)

11.25-11.30 Discussion

11.30-11.55 18.2 Imaging in the assessment of renovascular disease  
G Houston (UK)

11.55-12.00 Discussion

12.00-12.25 18.3 Renal artery intervention: what evidence is there?  
J Moss (UK)

12.25-12.30 Discussion

**12.30-13.00** **SESSION 19**  
**KEYNOTE LECTURE**  
Chairman: G Geroulakos (UK)

12.30-12.55 19.1 Liposuction for the management of lymphoedema  
H Brorson (Sweden)

12.55-13.00 Discussion

## WEDNESDAY 26<sup>th</sup> OCTOBER 2005 CONTINUED

**12.30-13.00**                    **SESSION 20**  
**KEYNOTE LECTURE**  
 Chairman:            J Fernandes e Fernandes (Portugal)

12.30-12.55    20.1    Genomic and proteomic applications to discovery in PAD  
 JP Cooke (USA)

12.55-13.00                    Discussion

**13.00-14.30**                    **LUNCH, POSTER VIEWING and EXHIBITION**

<b>PARALLEL SESSIONS</b>			
<b>14.30-16.00</b>	<b>SESSION 2</b> 4 <sup>th</sup> TransAtlantic Vascular Meeting (TAVM) <i>Argyll 1</i>	<b>SESSION 21</b> Lymphoedema Sponsored by medi UK Ltd. <i>Argyll 2</i>	<b>SESSION 22</b> Ultrasound, Cardiovascular Risk and Stroke Prevention <i>Castle 1 &amp; 2</i>

### 4<sup>th</sup> TransAtlantic Vascular Meeting (TAVM)

**14.30-16.00**                    **SESSION 2 – TAVM**  
 Chairmen:            L Norgren (Sweden)  
                               A Hirsch (UK)

14.30-16.00                    Concurrent Workshops  
*Small groups for discussion to discuss areas for the future*

Venous thromboembolism management: International perspectives on diagnosis and treatment  
 D Bergqvist (Sweden)  
 S Dean (USA)

Strides to improve international public awareness of PAD  
 A Hirsch (USA)  
 D Clement (Belgium)

To assess quality of life in patients with critical limb ischemia  
 G Moneta (USA)  
*Speaker to be confirmed*  
 R M Klevsgard (Sweden)

**14.30-16.00**                    **SESSION 21**  
**Lymphoedema – Sponsored by medi UK Ltd.**  
 Chairmen:            G Geroulakos (UK)  
                               *To be confirmed*

14.30-14.55    21.1    *Round table discussion*  
 The Mayo Clinic experience  
 R DePompolo (USA)

14.55-15.20    21.2    The management of lymphoedema should be a hospital based service  
 V Keeley (UK)

15.20-15.45    21.2    The management of lymphoedema should be community based  
 C Moffatt (UK)

15.45-16.00                    Panel discussion

## WEDNESDAY 26<sup>th</sup> OCTOBER 2005 CONTINUED

<b>14.30-16.00</b>	<b>SESSION 22</b> <b>Ultrasound, Cardiovascular Risk and Stroke Prevention</b> Chairmen: A Nicolaides (UK) D Mikhailidis (UK)
14.30-14.47	22.1 Carotid plaque characterisation and stroke prediction M Griffin (UK)
14.47-14.52	Discussion
14.52-15.09	22.2 The Boyd Orr study R Martin (UK)
15.09-15.14	Discussion
15.14-15.31	22.3 Ultrasound and markers of unstable atherosclerotic plaques A Nicolaides (UK)
15.31-15.36	Discussion
15.36-15.53	22.4 Lipid lowering and stroke prevention D Mikhailidis (UK)
15.53-15.58	Discussion
<b>16.00-16.30</b>	<b>TEA, EXHIBITION and POSTER VIEWING</b>

### PARALLEL SESSIONS

<b>16.30-17.30</b>	<b>SESSION 2 CONTINUED</b> <b>4<sup>th</sup> TransAtlantic Vascular Meeting (TAVM)</b> <i>Argyll 1</i>	<b>SESSION 23</b> <b>Prostaglandins</b> <b>Sponsored by Mitsubishi Pharma Corporation</b> <i>Argyll 2</i>	<b>SESSION 24</b> <b>New Aspects in Prophylaxis of CV Events in Patients with Diabetes</b> <b>Supported by Novartis Italy</b> <i>Castle 1 &amp; 2</i>
--------------------	--	--	--

**16.30-17.30** **4<sup>th</sup> TransAtlantic Vascular Meeting (TAVM)**  
Moderators: M Bacharach (USA)  
A Comerota (USA)

#### **C – Vascular Debates**

1. Angiogenesis causes improvement in exercise capacity in PAD after exercise training  
B Annex (USA)
2. Exercise induced metabolic changes causes improved exercise capacity after exercise training  
W Hiatt (USA)
1. Individuals with unilateral renal artery stenosis and two-drug hypertension should undergo renal PTA  
M Jaff (USA)
2. Individuals with unilateral renal artery stenosis and two-drug hypertension should not undergo renal PTA  
J Olin (USA)

#### **Summary and closing remarks**

## WEDNESDAY 26<sup>th</sup> OCTOBER 2005 CONTINUED

16.30-17.30

### SESSION 23

#### Prostaglandins

Sponsored by Mitsubishi Pharma Corporation

Chairmen: L Norgren (Sweden)  
A Muir (UK)

16.30-16.45 23.1 Perioperative iloprost and surgical revascularisation for PAD  
G de Donato (Italy)

16.45-16.50 Discussion

16.50-17.05 23.2 Beraprost in PAD  
E Mohler (USA)

17.05-17.10 Discussion

17.10-17.25 23.3 AS-013 in Fontaine Stage III/IV limb ischaemia  
J Belch (UK)

17.25-17.30 Discussion

16.30-17.30

### SESSION 24

New Aspects in Prophylaxis of CV Events in Patients with Diabetes  
Supported by Novartis Italy

Chairmen: *to be confirmed*  
S Coccheri (Italy)

16.30-16.45 24.1 Prophylaxis of CV events in patients with diabetes: benefits and limitations  
G Lowe (UK)

16.45-17.00 24.2 Antiplatelet agents in PAD: options, benefits and limitations  
F Violi (Italy)

17.00-17.15 24.3 Inhibition of thromboxane A<sub>2</sub> synthase and receptor lowers mortality in  
diabetic patients with PAD  
S Coccheri (Italy)

17.15-17.30 Panel discussion

19.30-late

### CONGRESS DINNER

Argyll Suite, Moat House Hotel

# SCIENTIFIC PROGRAMME - THURSDAY 27<sup>th</sup> OCTOBER 2005

## PARALLEL SESSIONS

<b>08.30-10.30</b>	<b>SESSION 25</b> <b>Joint Symposium with Diabetes UK</b> <b>Supported by an unrestricted educational grant from GlaxoSmithKline</b> <i>Argyll 1</i>	<b>SESSION 26</b> <b>The Role of Stents in the Superficial Femoral Artery</b> <b>Sponsored by Guidant</b> <i>Argyll 2</i>	<b>SESSION 27</b> <b>Joint Symposium Société Française de Médecine Vasculaire (SMFV)</b> <b>Raynauds phenomenon and Systemic Sclerosis</b> <b>Sponsored by the SMFV</b> <i>Castle 1 &amp; 2</i>
--------------------	---	--	---

**08.30-10.30**      **SESSION 25**  
**Joint Symposium with Diabetes UK**  
**Supported by an unrestricted educational grant from GlaxoSmithKline**  
**Insulin Resistance**  
Chairmen:      J Petrie (UK)  
                    J Connell (UK)

08.30-08.50    25.1    New insights into pathophysiology from the RISC study  
A Natali (Italy)

08.50-08.55                      Discussion

08.55-09.15    25.2    New molecules implicated in insulin resistance  
C Sutherland (UK)

09.15-09.20                      Discussion

09.20-09.40    25.3    New treatments targeted at insulin resistance  
C Bailey (UK)

09.40-09.45                      Discussion

09.45-10.05    25.4    New intervention trials with insulin sensitising agents  
M Fisher (UK)

10.05-10.30                      Panel discussion

**08.30-10.30**      **SESSION 26**  
**The Role of Stents in the Superficial Femoral Artery (SFA)**  
**Sponsored by Guidant**  
Chairmen:      E Minar (Austria)  
                    T Zeller (Germany)

08.30-08.55    26.1    Outcome after femoropopliteal stenting: influence of stent material and designs  
M Haumer (Austria)

08.55-09.20    26.2    Stent fractures in the SFA: a matter for concern?  
A Schmidt (Germany)

09.20-09.45    26.3    Balloon angioplasty vs primary stent implication in the SFA:  
results from randomized controlled trials  
E Minar (Austria)

09.45-10.10    26.4    New stent technologies: drug eluting stents, bioabsorbable stents  
T Zeller (Germany)

10.10-10.30                      Panel discussion

# THURSDAY 27<sup>th</sup> OCTOBER 2005 CONTINUED

08.30-10.30

## SESSION 27

**Joint Symposium Société Française de Médecine Vasculaire  
New Steps in the Vascular Approach of Systemic Scleroderma  
Sponsored by the SMFV**

Chairmen: P Carpentier (France)  
J Constans (France)

- 08.30-08.50 27.1 The lessons of an epidemiologic approach to Raynaud phenomenon and systemic scleroderma  
P Carpentier (France)
- 08.50-08.54 Discussion
- 08.54-09.14 27.2 Macrovascular disease in systemic scleroderma  
*Speaker to be confirmed*
- 09.14-09.18 Discussion
- 09.18-09.38 27.3 Arterial distensibility and systemic sclerosis  
J Constans (France)
- 09.38-09.42 Discussion
- 09.42-10.02 27.4 A new era in the management of pulmonary arterial hypertension related to scleroderma  
E Hachulla (France)
- 10.02-10.06 Discussion
- 10.06-10.26 27.5 Vascular treatments in systemic scleroderma  
C Denton (UK)
- 10.26-10.30 Discussion

10.30-11.00

## COFFEE, EXHIBITION and POSTER VIEWING

### PARALLEL SESSIONS

11.00-12.30	<b>SESSION 28</b> Research Papers Diabetes <i>Argyll 1</i>	<b>SESSION 29</b> Atherothrombosis Sponsored by Bristol-Myers Squibb <i>Argyll 2</i>	<b>SESSION 30</b> The Microcirculation in Vascular Disease Joint Symposium with Microcirculation Society of GB <i>Castle 1 &amp; 2</i>
12.30-13.10	<b>SESSION 31</b> Keynote Lecture <i>Argyll 1</i>	<b>SESSION 32</b> Keynote Lecture <i>Argyll 2</i>	<b>SESSION 33</b> Research Papers <i>Castle 1 &amp; 2</i>

11.00-12.30

## SESSION 28

**Joint Symposium on Insulin Resistance with Diabetes UK  
Supported by an unrestricted educational grant from GlaxoSmithKline**

### RESEARCH PAPERS – Diabetes

Chairmen: J Petrie (UK)  
P Poredos (Slovenia)

## THURSDAY 27<sup>th</sup> OCTOBER 2005 CONTINUED

- 11.00-11.10 28.1 The impact of diabetes on current revascularisation practice and clinical outcome in patients with critical lower limb ischaemia  
S Awad, C Karkos, F Serrachino-Inglott, S Butterfield, R Ashleigh, A Nasim (UK)
- 11.10-11.20 28.2 Early vascular lesions in subjects with metabolic syndrome and prediabetes  
EJ Diamantopoulos, E Andreadis, G Tsourous, P Katsanou, D Georgiopoulos, M Kakou, G Yfanti, K Nestora, SA Raptis (Greece)
- 11.20-11.30 28.3 Carotid wall alterations in subjects with impaired fasting glucose or impaired glucose tolerance  
EJ Diamantopoulos, E Andreadis, G Tsourous, P Katsanou, D Georgiopoulos, M Kakou, M Fotia, A Antoniou, SA Raptis (Greece)
- 11.30-11.40 28.4 The effect of laserotherapy on thrombosis/fibrinolytic process in patients with unstable angina  
IG Alizade, NT Aliyeva-Karayeva (Azerbaijan)
- 11.40-11.50 28.5 High mortality associated with peripheral arterial disease in elderly and old primary care patients: 3-year results of the getABI study  
C Diehm, HJ Trampisch, JR Allenberg, B v. Stritzky, R Haberl, M Mahn, B Dasch, D Pittrow, G Tepohl, H Darius (Germany)
- 11.50-12.00 28.6 The effect of a treated hypercoaguable state on the progression of premature peripheral atherosclerosis  
VJ Leijdekkers, AC Vahl (The Netherlands)
- 12.00-12.10 28.7 Seven-year follow-up after revascularisation of renal artery stenosis caused by fibromuscular dysplasia  
A Alhadad, I Mattiasson, K Ivancev, A Gottsäter, B Lindblad (Sweden)
- 12.10-12.20 28.8 Long-term results of infrainguinal bypass surgery  
SA Papoyan, KG Abalmasov (Russia)

### 11.00-12.30

#### **SESSION 29**

#### **Atherothrombosis in 2005**

#### **Sponsored by Bristol-Myers Squibb**

Chairmen: A Hirsch (USA)

G Agnelli (Italy)

- 11.00-11.17 29.1 Overview  
W Hiatt (USA)
- 11.17-11.22 Discussion
- 11.22-11.39 29.2 CASPAR & REACH  
I Baumgartner (Switzerland)
- 11.39-11.44 Discussion
- 11.44-12.01 29.3 To be confirmed
- 12.01-12.06 Discussion
- 12.06-12.23 29.4 Bringing the message home  
D Clement (Belgium)
- 12.23-12.28 Discussion

## THURSDAY 27<sup>th</sup> OCTOBER 2005 CONTINUED

11.00-12.30

### SESSION 30

#### Joint Symposium with Microcirculation Society of GB The Microcirculation in Vascular Disease

Chairmen: F Khan (UK)  
A Shore (UK)

11.00-11.25 30.1 Molecular biological regulation of angiogenesis in human physiology and pathology  
D Bates (UK)

11.25-11.30 Discussion

11.30-11.55 30.2 Microvasculature, diabetes and insulin resistance  
A Shore (UK)

11.55-12.00 Discussion

12.00-12.25 30.3 Oedema – role of the microcirculation in lymph formation and drainage  
P Mortimer (UK)

12.25-12.30 Discussion

12.30-13.00

### SESSION 31

#### KEYNOTE LECTURE

Chairman: E Diamantopoulous (Greece)

12.30-12.55 31.1 Metabolic and insulin resistance syndromes: how many more definitions do we need?  
B Balkau (France)

12.55-13.00 Discussion

12.30-13.00

### SESSION 32

#### KEYNOTE LECTURE

Chairman: S Novo (Italy)

12.30-12.55 32.1 Atherothrombosis  
*Speaker to be confirmed*

12.55-13.00 Discussion

12.30-13.10

### SESSION 33

#### RESEARCH PAPERS

Chairmen: P Mortimer (UK)  
C Diehm (Germany)

12.30-12.40 33.1 Botox injection heals digital ulcers and dramatically reduces  
Raynauds episodes for three months  
M Pritzker, A Van Beek  
(USA)

12.40-12.50 33.2 The lessons of an epidemiologic approach to Raynaud phenomenon and  
systemic scleroderma  
PH Carpentier  
(France)

12.50-13.00 33.3 Venous haemodynamics changes in lower limb lymphoedema  
JH Parmar, M Aslam, NJ Standfield  
(UK)

33.4 This oral has been withdrawn by the author

13.00-13.10 33.5 Vasospams as a presenting symptom of complex regional pain syndrome  
M Pritzker (USA)

# THURSDAY 27<sup>th</sup> OCTOBER 2005 CONTINUED

13.10-14.30

LUNCH, POSTER VIEWING and EXHIBITION

## PARALLEL SESSIONS

PARALLEL SESSIONS			
14.30-16.30	<b>SESSION 34</b> Joint Session between Vascular Independent Research and Education (VAS) and the Cochrane Collaboration <i>Argyll 1</i>	<b>SESSION 35</b> Joint Symposium with the Vascular Technologists <i>Argyll 2</i>	<b>SESSION 36</b> Research Papers Peripheral Arterial Disease <i>Castle 1 &amp; 2</i>

14.30-16.30

### SESSION 34

**Joint Session between VAS (Vascular Independent Research and Education) and the Cochrane Collaboration  
Education in Vascular Medicine/Angiology**

Chairmen: M Catalano (Italy)  
G Fowkes (UK)

14.30-14.55

34.1

The cultural independence of vascular medicine/angiology  
E Minar (Austria)

14.55-15.00

Discussion

15.00-15.25

34.2

The central role of vascular medicine/angiology in the vascular patient  
*Speaker to be confirmed*

15.25-15.30

Discussion

15.30-15.55

34.3

Contribution of Cochrane Collaboration to evidence based medicine  
H Maxwell (UK)

15.55-16.00

Discussion

16.00-16.25

34.4

Establishing education and training: The VAS Project  
M Catalano (Italy)

16.25-16.30

Discussion

14.30-16.30

### SESSION 35

**Joint Symposium Vascular Technologists  
Education in Vascular Medicine/Angiology**

Chairmen: R Levison (UK)  
A Jawien (Poland)

14.30-14.55

35.1

Brachial artery flow mediated dilatation to assess endothelial function - methodology and utility  
*Speaker to be confirmed*

14.55-15.00

Discussion

15.00-15.25

35.1

IMT – its clinical relevance  
P Poredos (Slovenia)

15.25-15.30

Discussion

15.30-15.55

35.2

A screening programme for PAD  
*Speaker to be confirmed*

15.55-16.00

Discussion

## THURSDAY 27<sup>th</sup> OCTOBER 2005 CONTINUED

- 16.00-16.25 35.3 Ankel brachial index as an indicator of mortality and cardiovascular disease: systematic review  
*Speaker to be confirmed*
- 16.25-16.30 Discussion
- 14.30-16.30** **SESSION 36**  
**RESEARCH PAPERS**  
Peripheral Arterial Disease  
Chairmen: G Lowe (UK)  
A Drooz (Austria)
- 14.30-14.40 36.1 Long segment SFA stenting - the dark sides: instent restenosis, clinical deterioration, and stent fractures  
OS Schlager, PD Dick, SS Sabeti, JA Amighi, WM Mlekusch, EM Minar, MS Schillinger (Austria)
- 14.40-14.50 36.2 Impact of length of lesion and stent balloon length on carotid velocities  
H Kalsi, J Bartholomew, S Begelman, A Almahameed, H Gurm, J Yadav (USA)
- 14.50-15.00 36.3 Vascular reconstruction for popliteal artery aneurysms  
M Hamish, A Lockwood, C Cpsgrove, A Walker, D Wilkins, S Ashley (UK)
- 15.00-15.10 36.4 Femoro-distal vein graft bypass and outcomes of a vein graft surveillance program  
AS McKeown, AHA Quddus, M Welch (UK)
- 15.10-15.20 36.5 Abdominal aortic aneurysm repair in octogenarians: open or endovascular?  
AHA Quddus, AS McKeown, M Welch (UK)
- 15.20-15.30 36.6 Acute popliteal and infrapopliteal arterial occlusions - endovascular therapy  
M Bulvas, Z Sommerova, R Urbanova (Czech Republic)
- 15.30-15.40 36.7 A comparison of patency and re-intervention rates between reversed and in-situ long saphenous vein for femoro-distal bypass graft  
AS McKeown, AHA Quddus, M Welch (UK)
- 15.40-15.50 36.8 Antibiotic prophylaxis in vascular surgery: survey of vascular surgeons in UK, Ireland  
S Taribagil, C Kyriakides (UK)
- 16.30** **CLOSE OF MEETING**

**The programme is correct at the time of printing and the Secretariat accepts no liability for changes made at a later date.**